The serotonin type-3 (5-HT 3 ) antagonists represent a significant advance in the prevention of acute nausea and vomiting (N/V) from highly emetogenic chemotherapy. We sought to determine if any differences in efficacy or adverse effects exist between two such agents, ondansetron and granisetron, during conditioning therapy for hematopoietic stem cell transplantation (HSCT). Patients were randomized to receive either ondansetron 0.15 mg/kg intravenously every 8 h or granisetron 10 lg/kg intravenously daily. Additionally, all patients received scheduled dexamethasone and lorazepam. Prophylaxis was continued until 24 h after completion of chemotherapy. Nausea and distress were measured subjectively with visual analog scales and emetic episodes were quantified. Of the 110 randomized patients, 96 were evaluable for efficacy and safety. No significant differences in efficacy were observed between the ondansetron-and granisetron-treated patients, evaluated by comparing the degree of nausea and distress, number of emetic episodes and overall control of emesis. The adverse effects were also comparable and no patients were removed from study because of severe toxicities. This trial demonstrates that ondansetron and granisetron are equally effective at preventing acute N/V associated with conditioning therapy frequently used for HSCT. The agent of choice should be based on drug acquisition cost or preference.
effects of chemotherapy. In the setting of hematopoietic stem cell transplantation (HSCT), where high doses of chemotherapy are generally employed, these symptoms are almost universal and can have profound clinical and psychological implications for the patient. One significant advance in the prevention of chemotherapy-induced N/V (CINV) has been the introduction of the serotonin type-3 (5-HT 3 ) receptor antagonists, which inhibit the binding of serotonin to vagal afferent fibers located in the gastrointestinal tract and 5-HT 3 receptors in the vomiting center. 1 Currently, four 5-HT 3 receptor antagonists are approved in the United States for the prevention of acute N/V associated with cancer chemotherapy, including ondansetron (Zofran s , GlaxoSmithKline, Research Triangle Park, NC, USA), granisetron (Kytril s , Roche Laboratories, Nutley, NJ, USA), dolasetron (Anzemet s , Aventis Pharmaceuticals, Kansas City, MO, USA), and palonosetron (Aloxit, MGI Pharma Inc., Minneapolis, MN, USA). Palonosetron is also indicated for the prevention of delayed N/V associated with moderately emetogenic chemotherapy. Outside of the HSCT setting, numerous studies have concluded that these agents provide equivalent control of N/V induced by highly emetogenic chemotherapy when administered at equipotent doses. [2] [3] [4] [5] [6] [7] [8] Although three of these agents have been extensively studied in HSCT patients over the last 8 years, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] limited data directly comparing these agents is available. [21] [22] [23] Ondansetron, the first 5-HT 3 receptor antagonist approved in the United States, has been the most widely studied and is most effectively used in combination with corticosteroids for prevention of CINV; granisetron's effects are also enhanced with the use of corticosteroids.
This study was designed to directly compare the efficacy and adverse effects of ondansetron and granisetron, in combination with other antiemetics, for the prevention of acute CINV associated with common, nontotal body irradiation (TBI)-containing conditioning regimens utilized in HSCT.
Patients and methods

Patient eligibility
All in-patients undergoing autologous or allogeneic HSCT for any malignancy who gave written informed consent were eligible for enrollment in the study. Patients were excluded if they were scheduled to receive TBI as part of their conditioning regimen or any radiation therapy within 24 h of study initiation or during the study period. Other exclusion criteria included (1) nausea or vomiting within 24 h prior to initiation of therapy, (2) receipt of any medication with antiemetic activity within 24 h of study initiation or during the study period such as metoclopramide or dronabinol, and (3) known hypersensitivity to any 5-HT 3 receptor antagonist or other study medication. Permitted medications included antihistamines as a premedication for blood transfusions and triazolam or diphenhydramine for insomnia. Patients were required to meet all institutional requirements for HSCT with respect to laboratory tests, physical examination, vital signs, and performance status. Patients must have been X18 years of age, and a b-hCG test was performed to rule out pregnancy in female patients.
Study design
This was a prospective, randomized, double-blind trial conducted at two hospitals, both affiliated with the University of Texas Health Science Center HSCT Program. Patients were evaluated and enrolled within 1 week of study initiation.
Patients were randomized according to a computergenerated scheme to either the granisetron group or ondansetron group in a 1:1 distribution. The randomization took into account the conditioning regimen, prior history of CINV, and previous alcohol or drug use, to assure that both arms were balanced regarding these clinical parameters.
Treatment plan
Following consent, eligible patients were randomized to receive either intravenous granisetron 10 mg/kg daily or ondansetron 0.15 mg/kg intravenously every 8 h. Additionally, both treatment groups received intravenous dexamethasone 10 mg daily and lorazepam 1 mg intravenously every 8 h. To maintain the study blind, patients randomized to receive granisetron also received 50 ml of 0.9% normal saline as a placebo twice daily (Figure 1 ). The first dose of study drug was administered 30 min prior to the first scheduled dose of chemotherapy and continued for 24 h after the completion of chemotherapy. Patients who received busulfan and cyclophosphamide as their conditioning regimen did not begin the study drug until the cyclophosphamide was administered, because busulfan alone has little emetogenic potential. The total number of days of study drug administration was dependent on the chemotherapy regimen administered. Rescue medication with prochlorperazine 10 mg intravenous every 6 h as needed was available if the patient had three to five emetic episodes within a 24 h period or if the patient requested the medication. Patients were removed from the study if they experienced a Southwestern Oncology Group (SWOG) grade 3 or 4 toxicity, other than myelotoxicity, unless it was believed to be unrelated to the study medication. 24 
Statistical analyses
It was assumed that the therapy would be 75-95% effective in preventing N/V in this patient population. In order to detect a difference in response of 20% between the two groups with a P-value of 0.05 and power of 80%, a total of 98 patients were required to complete the study (49 patients per treatment arm). Nausea, distress, and overall control of emesis at each day were analyzed using Fisher's exact test due to small expected cell frequencies for certain categories of response. Nausea and distress were categorized into none to mild and moderate to severe and overall emetic control was grouped into complete to major response vs minor response to failure. Differences in toxicity, measured as the number of adverse events per subject between the two treatment groups over the entire study, were analyzed with Wilcoxon's rank-sum test while incidence of specific events was compared across the two groups using the w 2 or Fisher's exact test as appropriate. For the baseline demographics, Wilcoxon's rank-sum tests were performed for the continuous variables and Fisher's exact test for the categorical variables. The computer software used for the statistical analyses was Stata v. 8 (College Station, TX, USA).
Efficacy measurements
The primary objectives of the study were to compare the efficacy of granisetron and ondansetron in the prevention of acute N/V in this patient population by assessing nausea, distress, number of emetic episodes, and overall control of emesis until 24 h after completion of chemotherapy. Prevention of nausea/vomiting in stem cell transplantation T Walsh et al Nausea and distress were subjectively evaluated using the visual analog scale (VAS). For nausea, the VAS consisted of a 100 mm line ranging from 'no nausea' (VAS ¼ 0 mm) to 'the worst possible nausea' (VAS ¼ 100 mm). The proper use of the scale was described to the patient. Patients were asked to place a mark on the line corresponding to the worst degree of nausea that they experienced within the past 24 h. For distress, the VAS consisted of a 100 mm line ranging from 'not upset at all' (VAS ¼ 0 mm) to 'the most upset you've ever been' (VAS ¼ 100 mm) within the past 24 h. As with nausea, patients were asked to place a mark on the line corresponding to the greatest degree of distress that they experienced within the past 24 h. Nausea and distress were measured at baseline and daily throughout the study period. Mild nausea or distress were defined as a VAS score of p30 mm, moderate nausea or distress were defined as a VAS score of 31-60 mm, and severe nausea or distress were defined as a VAS score of 61-100 mm.
An emetic episode was defined as a single vomit (ie, expulsion of stomach contents) or one to five retches (ie, an attempt to vomit) occurring within a 5-min period. Each episode of vomiting was recorded and quantified.
Overall control of emesis was also documented. Response criteria for control of emesis were ranked as complete response, major response, minor response, and failure and included emesis plus degree of nausea (Table 1) .
Patients who experienced six or more emetic episodes within 24 h during the study period were considered treatment failures and were subsequently treated at the physician's discretion.
Safety assessments
Adverse events were quantified and graded for severity using the SWOG toxicity grading criteria. 24 Patients were discontinued from the study if they experienced a SWOG grade 3 or 4 adverse event that was felt to be related to the study medication and not to the HSCT conditioning regimen, if the patient requested to be removed from the study, or if the investigator felt that it was unsafe to continue the study medication for any reason.
Results
Patient characteristics
A total of 110 patients were randomized and enrolled into the study. However, 14 patients were withdrawn for various reasons: (1) five patients had baseline nausea or vomiting prior to receiving the first dose of study drug, (2) five patients received medications with antiemetic activity that were not permitted during the study period, (3) one patient received the wrong study drug, (4) one patient developed severe opiate-induced confusion and hand tremors and was unable to complete the VAS, and (5) two patients received the scheduled antiemetics incorrectly. Of the 96 assessable patients, 46 patients received granisetron and 50 patients received ondansetron. Patient demographics are listed in Table 2 . The treatment groups were well balanced with no statistically significant differences in age, gender, diagnosis, previous history of N/V, alcohol intake, or chemotherapy regimen.
Nausea and distress
Patients did not receive study medication for the same duration because of the different conditioning regimens administered. Therefore, nausea and distress were evaluated on a daily basis. In order to detect a statistically meaningful difference, categories of nausea and distress were ranked as none to mild (VAS, 0-30 mm) and moderate to severe (VAS, 31-100 mm). The comparative results of moderate-to-severe nausea are depicted in Figure 2 . Table 1 Daily control of emesis
Category Definition
Complete response No emetic episodes and none-to-mild nausea Major response One to two emetic episodes and none-to-moderate nausea or no emetic episodes and moderate nausea Minor response Three to five emetic episodes and any degree of nausea or zero to two emetic episodes and severe nausea Failure X6 emetic episodes and any degree of nausea 
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Regardless of severity, control of nausea declined throughout the study duration, and it appears as though the patients in the granisetron arm had a higher incidence of nausea on day 6. However, no statistically significant differences in the degree of nausea occurred in either the granisetron group or ondansetron group on any given treatment day (range, P ¼ 0.563-1.000). Although these two agents appear equally effective, it must be noted that as a result of the small number of patients who received antiemetics by day 6, a small difference may be undetectable. The degree of distress for either treatment group was low throughout the study period. Once again, both study drugs produced a similar incidence of distress until day 6 of the study period, when patients receiving granisetron appeared to fare worse, but this difference did not attain statistical significance (range, P ¼ 0.080-1.000).
Nausea and distress were also evaluated based on the chemotherapy regimen administered (ie, busulfan/cyclophosphamide-containing regimens vs other regimens). In the patients receiving nonbusulfan/cyclophosphamide-containing regimens, no significant differences between the two treatment groups occurred, except for distress at day 1, when a slightly higher incidence of patients receiving granisetron experienced moderate-to-severe distress (P ¼ 0.047). A slightly higher incidence of patients receiving granisetron experienced moderate distress. The analysis was otherwise unable to detect any differences between the two treatment groups despite the type of chemotherapy regimen administered.
Vomiting episodes and control of emesis
The median number of emetic episodes was 3 (range, 0-15) for the granisetron-treated group and 1 (range, 0-9) for the ondansetron-treated group (P ¼ 0.228). The overall control of emesis was similar between treatment groups (Table 3) . Although control of emesis declined throughout the study period, the majority of patients had a complete or major response. Only five (10.9%) and four (8%) patients receiving granisetron and ondansetron, respectively, had treatment failures during the study period.
Adverse events
The most common adverse event that could be attributed to the study drugs was hiccups (Table 4) . Diarrhea was also common, however, most of the patients who developed diarrhea were also receiving high-dose etoposide, which may have played a significant role in the development of this complication. Other common adverse effects that occurred included constipation, headache, drowsiness, hypersensitivity and tremors. Once again, the patients were receiving other medications, including dexamethasone, lorazepam, and prochlorperazine, that may have (7) 5 (14) 6 (17) 4 (17) 5 (36) Prevention of nausea/vomiting in stem cell transplantation T Walsh et al contributed to these adverse events. The median number of adverse effects was one for both the ondansetron-and granisetron-treated groups (range, 0-3 (ondansetron); range, 0-5 (granisetron)). The incidence of adverse events was similar between the treatment groups (P ¼ 0.294). Additionally, no patients were removed from the study because of severe toxicities.
Discussion
This study was designed to compare the differences in efficacy and adverse effects between intravenous ondansetron and granisetron in combination with dexamethasone and lorazepam over the course of standard conditioning regimens administered in preparation for HSCT. Based on comparative studies using conventional chemotherapy, it was not surprising that these agents, administered intravenously, were found to be equivalent for all subjective and objective measures of this study in HSCT recipients. Failure of emesis control occurred in only five (10.9%) and four (8%) of the granisetron-and ondansetron-treated patients, respectively. Unfortunately, as chemotherapy continued, daily control of all end points decreased with loss of efficacy for both agents.
The regimen selected for this study was based on the current practice at our institution at the time the protocol was developed. Multiple phase II studies in the HSCT setting have been published since enrollment into this trial began. These studies have substantiated the efficacy of granisetron and ondansetron for prevention of N/V associated with high-dose conditioning regimens, however, different dosing strategies and end points have made comparisons of these results difficult. One such study was conducted by Abbott et al 18 and evaluated the efficacy of intravenous granisetron plus intravenous dexamethasone 10 mg administered daily until 24 h after conditioning therapy was complete. Only 1% of 100 patients enrolled failed to respond, however, the response criteria were different than those used in our study. Additionally, patients receiving single-agent cyclophosphamide for stem cell mobilization were included in the study by Abbott, which, in our experience, cause a lower incidence of N/V compared to commonly used multi-agent conditioning regimens. Interestingly, most patients in this study were younger and female and would, therefore, be expected to have a higher degree of N/V, which was not the case when compared with the results of our study, 84% of which were men.
Since the initiation of this trial, there have been two publications comparing granisetron with ondansetron for the prevention of N/V with conditioning therapy for HSCT. 21, 22 Kalaycio et al 21 randomized 48 adult patients with breast cancer to receive granisetron or ondansetron as a continuous intravenous infusion for a total of 7 days, with daily intravenous dexamethasone. Efficacy measures included subjective nausea, mean number of emetic episodes, number of salvage antiemetics, and days to first salvage antiemetic. Of the 45 evaluable patients, no significant differences in efficacy or adverse effects between the two treatment groups were observed. Although nausea was graded subjectively, only 50% of the patients completed diaries, and the differences between the treatment groups were not reported. However, 73% of all patients enrolled in the study experienced moderate-tosevere nausea. Another comparative review conducted by Orchard et al 22 randomized 136 pediatric and adult patients to receive ondansetron by continuous intravenous infusion or granisetron intravenously every 12 h. All patients also received dexamethasone, and those o18 years old additionally received scheduled lorazepam and promethazine. Once again, no significant differences were observed between ondansetron-and granisetron-treated patients.
Comparisons of the results of our study with the other phase III study results are difficult because of the differences in efficacy parameters, patient populations, and dosing strategies. These varied approaches are common limitations when evaluating antiemetic studies. Most patients in our study were recruited from a Veterans' Administration hospital and, therefore, included primarily older men with non-Hodgkin's lymphoma and multiple myeloma, whereas the Kalaycio study included only middle-aged women with breast cancer and the Orchard study included pediatric and adult patients who received primarily TBI-containing conditioning regimens. Our dosing strategy provided intermittent schedules of all antiemetics, whereas the other studies varied in their approaches. These varied approaches could possibly impact the results, although the data on intermittent vs continuous infusion ondansetron in HSCT suggests that dosing strategy does not matter. One unique feature of our analysis is the evaluation of total emesis control. We believe that it is important to look at the total impact of emesis and nausea, as they both negatively affect the patient's quality of life, however, by doing this our results may appear worse than other published studies. The ideal strategy would be to evaluate one disease state and one conditioning regimen to eliminate multiple factors that could influence the comparative responses between antiemetics, however, accrual in such a study would be difficult to complete in a reasonable time frame.
We conducted this randomized, double-blind study to compare the efficacy and toxicity of two different 5HT 3 antagonists for the prevention of N/V during non-TBIcontaining conditioning therapy for HSCT. Standardized measures of nausea revealed no significant difference between granisetron and ondansetron and, although control of emesis decreased throughout the treatment period, the degree of success was similar between the two treatment groups. Additionally, the overall incidence of adverse effects was similar, and no patients were removed from study because of severe toxicities. Based on these results, the choice of therapy should be based on drug acquisition cost. Future clinical trials should focus on oral antiemetics to accommodate outpatient transplant practice models or novel pharmacologic entities such as aprepitant (Emend s , Merck & Co. Inc., Whitehouse Station, NJ, USA), a neurokinin-1 receptor antagonist, in an attempt to improve emesis control throughout conditioning chemotherapy.
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